About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT06735924

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatot...

Lead sponsor: University of Alabama at Birmingham•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Kyle D Wood, MD

CONTACT

2059968765 [email protected]

Sonia Fargue, PhD

CONTACT

2059756932 [email protected]

Sponsors

Lead Sponsor

University of Alabama at Birmingham

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Urinary oxalate excretion is derived from both dietary sources and endogenous synthesis. This study will use a low-oxalate controlled diet, repeat fasted urine collections and 24-hr urine collections on a low-oxalate diet, to determine the daily rate of endogenous oxalate synthesis in individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•age \>18 years
•History of MASLD, with liver fat content \> 5%
•Normal kidney function
•Stable medication for at least 1 month for diabetes mellitus if any
•Willingess to ingest fixed diets and stop dietary supplements for the study and come to UAB for visits

Exclusion Criteria

•Age \< 18 years
•Inaccurate 24-hour urine collections
•Liver fat content \<5%
•Liver cirrhosis
•Evidence of other chronic liver disease, viral hepatitis
•history of alcoholism within 2 years of enrollment
•Contra-indication to Magnetic Resonance Imaging
•Chronic kidney disease with estimated Glomerular Filtration rate \< 60 ml/min/1.73m2
•Type 1 Diabetes Mellitus or treatment with insulin
•Uncontrolled diabetes
•Pregnancy, lactation or intention to be
•Uncontrolled hypertension
•Use of weight loss medication, SGLT2 inhibitors, GLP-1 receptor agonists, osteoporosis medication, chronic NSAID
•History of gastric or intestinal surgery or resection that could potentially alter oxalate absorption
•Chronic fat malabsorption
•Use of immunosuppressive medications
•Known immuno-compromised status
•Active malignancy or treatment for malignanacy within the last 12 months

Related studies

Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis

NCT07552727 · Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784 · MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), and more

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

NCT07440511 · MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

RECRUITINGPhase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

NCT06843148 · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 19, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment28

Start dateApr 2023

Last updatedDec 19, 2025

Condition

MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease

Locations shown

University of Alabama at Birmingham

Birmingham, Alabama

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions